- Home
- IONS vs BEP Comparison
IONS vs BEP Comparison
Compare IONS & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IONS | BEP |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 5870 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.3B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | IONS | BEP |
|---|---|---|
| Price | $54.09 | $32.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 10 |
| Target Price | ★ $93.36 | $35.70 |
| AVG Volume (30 Days) | ★ 4.4M | 1.1M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.71% |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.09 |
| Revenue Next Year | $77.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.37 | $24.13 |
| 52 Week High | $86.74 | $38.12 |
Technical Indicators
Market Signals| Indicator | IONS | BEP |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 50.04 |
| Support Level | $50.01 | $31.71 |
| Resistance Level | $57.48 | $34.47 |
| Average True Range (ATR) | 2.03 | 1.19 |
| MACD | 0.66 | 0.18 |
| Stochastic Oscillator | 68.16 | 53.44 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.